Oral N-Acetyl Cysteine Lowered IL 6 Level Among Stage V Chronic Kidney Disease Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)
Main Author: | Nurhayatun, Evi; Internal Medicine Department, Medical Faculty of Sebelas Maret University Surakarta Indonesia |
---|---|
Format: | Article info application/pdf eJournal |
Bahasa: | eng |
Terbitan: |
Faculty of Medicine
, 2017
|
Subjects: | |
Online Access: |
http://journal.uii.ac.id/index.php/JKKI/article/view/8957 http://journal.uii.ac.id/index.php/JKKI/article/view/8957/pdf-1 |
Daftar Isi:
- Background. IL 6 level is increased in stage V CKD patients on CAPD. N-Acetyl Cysteine is a compound containing thiol with antioxidant and anti-inflammatory effects.Objective. To examine the effect of oral NAC on IL 6 level in stage V CKD patients on CAPD.Method. An experimental research with Randomized Double Blind Control Trial, involving 30 CKD patients on CAPD in Dr Moewardi Hospital. They were divided into control group/placebo (15 patients) and oral NAS treatment group (15 patients). IL 6 level was measured before and after 8 weeks of treatment.Result. Level of IL 6 before and after treatment in control group were (8.13 + 7.62 vs 11.16 + 8.32 , p= 0,001), significantly (p<0,001). Level of IL 6 before and after treatment in treatment group were (9.72 + 7.29 vs 6.09 + 3.82, p = 0,002); lowered significantly (p<0,05).Conclusion. Oral NAC lowered the level of IL 6 in stage V CKD patients on CAPD.